InNexus Biotechnology Inc., a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL), announced that it has received notices of allowance on several of its patent applications both in the United States Patent & Trademark Office (USPTO) and in the European Patent Office (EPO) covering its DXL technology.

The patents following issuance will be titled "Therapeutic applications of noncovalent dimerizing antibodies" in the US and "Method of affinity cross-linking biologically active, immunogenic peptides to antibodies" in Europe, and relate to the company's ability to develop and manufacture DXL antibodies. The new patents name InNexus scientists as inventors and are solely owned by InNexus.

"This significantly expands the intellectual property protection of our exclusive DXL technology and continues to demonstrate both its potential as a novel and versatile therapeutic drug development system. Obtaining broad patent protection of technology is not only essential to the success of a biotech company, it's the currency of our business", said Jeff Morhet, chairman and CEO of InNexus. "We are very pleased that we will be expanding our DXL patent portfolio both here in the US and abroad and we will continue to aggressively pursue broad protection of the various aspects of DXL technology. A solid patent portfolio will allow us to drive value into the company with the potential for future licensing deals or outright sales of our maturing pre-clinical candidates."

Dynamic Cross Linking (DXL) technology seeks to improve upon the therapeutic potency of monoclonal antibody products by increasing target antigen binding, enhancing antibody effector functions, and installing new properties into antibodies such as the ability to trigger apoptosis, or "cell suicide". Put simply, DXL allows antibodies to achieve a higher level of therapeutic usefulness.